



Press release – Toulouse/Lyon, (March 10, 2022)


**VirHealth SAS and NeoVirTech SAS announce the creation of a strategical alliance to create one of the most advanced private virus disinfection platform in Europe.**

VirHealth and NeoVirTech join their virology expertise to provide customers one of the most extended virus disinfection measurement and R&D platform in France and in Europe. This alliance will allow the partners to combine their respective expertise in an integrated offer dedicated to increase knowledge in virus persistence in the environment, virus disinfection procedure and to provide customer state of the art models for the measurement of disinfection procedures using innovative and standardized approaches.

*An alliance to foster innovation*

VirHealth SAS is a French biotechnology company focusing its activity on the measurement of virucidal/antiviral activities of products, devices, and technologies for disinfection using standardized and bespoke experimental approaches in an ISO9001 environment. The company provides services to investigate virucidal activity of disinfectant products and equipment according to FR/EN/ASTM standards and has a strong expertise in the evaluation of the antiviral activity of surface, materials, and textiles. Moreover, VirHealth develops bespoke decontamination procedures for analyzing of equipment and technologies (radiation, chemical, physical) according to specific customer needs.






NeoVirTech is a French biotechnology company focusing its activity on antiviral discovery and virus/viral vector imaging. The company develops image-based readout for virology services and high content imaging of virus infection. Using innovative tagging approach (like ANCHOR™) they have the ability to follow infection and viral replication in living cells. The company uses its virus collection to discover antiviral molecules and measure the disinfection potential of decontamination procedures on a broad variety of viruses impacting human and animal health.

By combining their services and expertise, the strategical alliance between VirHealth and NeoVirTech creates the largest virology platform dedicated to the measurement and validation of disinfection procedures, from R&D phase to validation in standardized environment.

NeoVirTech brings to the alliance its collection of autofluorescent viruses, high throughput imaging techniques and innovative models of virus contamination testing (such as the use of living human skin). NeoVirTech is equipped with high content screening microscope combined to pipetting robots in BSL2, BSL2+ and BSL3 environment.



VirHealth brings its expertise in standardized and normative testing of viral disinfection methods with a wide experience in surface decontamination and its collection of animal and human viruses. VirHealth has access to qualified BSL2 and BSL3 laboratories.

The combined expertise will allow the partners to propose the full value chain for evaluation of disinfection methods, from the pure R&D part involving the rapid screening of a large number of disinfection conditions (NeoVirTech) to the qualification of the solution using normative procedures (VirHealth).

*“We are very proud to enter this strategical alliance with VirHealth. This alliance will allow us to provide our customer the best virology platform open to people interested in testing solution against infectious diseases. These solutions can be small molecules, disinfection methods, functionalized materials and so on. The join expertise of our structure will ensure that our customer have access to the best virology platform in France and maybe in Europe, from R&D*

*phase to normative validation, with a strong emphasis on communication and marketing applications.”*

Dr Franck Gallardo, CEO NeoVirTech SAS

*"The creation of this strategic alliance with the company NeoVirTech enables setting up a global and unique experimental approach in order to meet both clients' needs and the necessity of offering of innovative experimental strategies to respond to the technical challenges of tomorrow. This common expertise will allow to meet numerous challenges identified for managing of virological contamination and viral dissemination.*

Dr Vincent Moulès, CEO of VirHealth SAS



NeoVirTech develops autofluorescent viruses and viral vectors for imaging and discovery of novel antiviral drug candidates in the fields of human health, animal health and biodefense markets. The company has a catalog of viruses and fluorescent vectors in constant expansion and offers access to its proprietary ANCHOR™ technology, the only non-invasive technique to detect viral DNA replication inside living cells. Since the Covid-19 pandemic, the company is actively involved in SARS-CoV-2 screening campaign and measurement of disinfection procedures.

For more information: [www.neovirtech.com](http://www.neovirtech.com) - Press contact: [contact@neovirtech.com](mailto:contact@neovirtech.com)



VirHealth, independent laboratory, specialized in virology, offers a wide range of standardized testing as well as the bespoke assays and innovative and experimental procedures according to specific clients' conditions in order to determine virucidal activities of products, equipment and disinfection technologies.

For more information: [www.virhealth.fr](http://www.virhealth.fr) - Contact: [y.marie@virhealth.fr](mailto:y.marie@virhealth.fr)